Checkpoint Therapeutics(CKPT.US)向美国FDA提交其PD-L1靶向抗体上市申请

智通财经网07-04

智通财经APP获悉，日前，Checkpoint Therapeutics(CKPT.US)宣布已向美国FDA重新提交其PD-L1靶向抗体cosibelimab的生物制品许可申请(BLA)，用以治疗转移性或局部晚期皮肤鳞状细胞癌(cSCC)患者，这些患者不适合接受根治性手术或放射疗法。资料显示，Cosibelimab是一款潜在的差异化、高亲和力、全人源IgG1亚型单抗，可直接与PD-L1结合以阻断...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2448641864?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20240704/20240704103720_42181.png?x-oss-process=image/format,jpg/quality,Q_80","is_english":false,"pubTime":"2024-07-04 10:37","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2448641864","market":"sg","top_or_hot":-1,"title":"Checkpoint Therapeutics(CKPT.US)向美国FDA提交其PD-L1靶向抗体上市申请","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，日前，Checkpoint  Therapeutics(CKPT.US)宣布已向美国FDA重新提交其PD-L1靶向抗体cosibelimab的生物制品许可申请(BLA)，用以治疗转移性或局部晚期皮肤鳞状细胞癌(cSCC)患者，这些患者不适合接受根治性手术或放射疗法。资料显示，Cosibelimab是一款潜在的差异化、高亲和力、全人源IgG1亚型单抗，可直接与PD-L1结合以阻断...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1145432.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Checkpoint Therapeutics(CKPT.US)向美国FDA提交其PD-L1靶向抗体上市申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCheckpoint Therapeutics(CKPT.US)向美国FDA提交其PD-L1靶向抗体上市申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-04 10:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1145432.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，日前，Checkpoint  Therapeutics(CKPT.US)宣布已向美国FDA重新提交其PD-L1靶向抗体cosibelimab的生物制品许可申请(BLA)，用以治疗转移性或局部晚期皮肤鳞状细胞癌(cSCC)患者，这些患者不适合接受根治性手术或放射疗法。资料显示，Cosibelimab是一款潜在的差异化、高亲和力、全人源IgG1亚型单抗，可直接与PD-L1结合以阻断...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1145432.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PD","symbol_name":"PagerDuty, Inc.","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1145432.html","article_id":"2448641864","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20240704/20240704103720_42181.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448641864","pubTimestamp":1720060652,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"日前，Checkpoint Therapeutics(CKPT.US)宣布已向美国FDA重新提交其PD-L1靶向抗体cosibelimab的生物制品许可申请(BLA)。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PD":"PagerDuty, Inc.","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4139":"生物科技","LENZ":"Therapeutics","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4023":"应用软件","CKPT":"Checkpoint Therapeutics, Inc."},"translate_title":"Checkpoint Therapeutics (CKPT.US) submits its PD-L1-targeted antibody marketing application to the US FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CKPT":1,"LENZ":1,"PD":1},"content_text":"智通财经APP获悉，日前，Checkpoint  Therapeutics(CKPT.US)宣布已向美国FDA重新提交其PD-L1靶向抗体cosibelimab的生物制品许可申请(BLA)，用以治疗转移性或局部晚期皮肤鳞状细胞癌(cSCC)患者，这些患者不适合接受根治性手术或放射疗法。资料显示，Cosibelimab是一款潜在的差异化、高亲和力、全人源IgG1亚型单抗，可直接与PD-L1结合以阻断PD-L1与PD-1和B7.1受体的相互作用。2023年7月，Checkpoint公布cosibelimab在局部晚期和转移性cSCC患者中关键研究的长期数据。分析显示，患者应答随着时间的推移不断加深，客观缓解率达55%。其中局部晚期cSCC患者的完全缓解率为26%；转移性cSCC患者的完全缓解率为13%。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448641864"}